| Followers | 25 |
| Posts | 1901 |
| Boards Moderated | 0 |
| Alias Born | 06/15/2007 |
Tuesday, March 07, 2023 1:31:05 PM
Amarin Announces New REDUCE-IT® Data. March 5, 2023.
DUBLIN, Ireland and BRIDGEWATER, N.J., March 05, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced a new analysis from the VASCEPA/VAZKEPA (icosapent ethyl) cardiovascular outcomes REDUCE-IT study showing the effectiveness of VASCEPA®/VAZKEPA® in patients with recent acute coronary syndrome (<12 months before randomization). This post-hoc analysis showed that icosapent ethyl (IPE) substantially and significantly reduced the risk of first and total ischemic events by 37% and 36% respectively in patients with recent acute coronary syndrome (ACS) without increasing bleeding, supporting early initiation of IPE after ACS. The data were presented at the American College of Cardiology’s 72nd Annual Scientific Session together with the World Heart Federation’s World Congress of Cardiology in New Orleans, LA.
https://healthstockshub.com/news/nasdaq/amrn/amarin-announces-new-reduce-it-data-at-acc-23-wcc-showing-benefit-of-vascepa-vazkepa-icosapent-ethyl-in-high-risk-patients-with-a-recent-acute-coronary-syndrome-event
DUBLIN, Ireland and BRIDGEWATER, N.J., March 05, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced a new analysis from the VASCEPA/VAZKEPA (icosapent ethyl) cardiovascular outcomes REDUCE-IT study showing the effectiveness of VASCEPA®/VAZKEPA® in patients with recent acute coronary syndrome (<12 months before randomization). This post-hoc analysis showed that icosapent ethyl (IPE) substantially and significantly reduced the risk of first and total ischemic events by 37% and 36% respectively in patients with recent acute coronary syndrome (ACS) without increasing bleeding, supporting early initiation of IPE after ACS. The data were presented at the American College of Cardiology’s 72nd Annual Scientific Session together with the World Heart Federation’s World Congress of Cardiology in New Orleans, LA.
https://healthstockshub.com/news/nasdaq/amrn/amarin-announces-new-reduce-it-data-at-acc-23-wcc-showing-benefit-of-vascepa-vazkepa-icosapent-ethyl-in-high-risk-patients-with-a-recent-acute-coronary-syndrome-event
Bullish
Recent AMRX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/12/2026 08:10:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/11/2026 10:56:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 08:28:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 08:27:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 08:26:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 08:24:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 08:22:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:15:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:09:04 PM
- Amneal Reports First Quarter 2026 Financial Results • GlobeNewswire Inc. • 05/07/2026 08:01:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/27/2026 08:12:24 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/23/2026 08:18:56 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/22/2026 09:00:19 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/22/2026 08:28:17 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/22/2026 08:26:18 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/22/2026 08:24:41 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/22/2026 08:23:25 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/22/2026 10:24:08 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/22/2026 10:22:26 AM
- Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader • Business Wire • 04/22/2026 10:17:00 AM
- Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance • GlobeNewswire Inc. • 04/22/2026 10:00:00 AM
- Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY® • GlobeNewswire Inc. • 04/20/2026 12:00:00 PM
- Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S. • GlobeNewswire Inc. • 04/14/2026 12:00:00 PM
- Amneal Launches Bimatoprost Ophthalmic Solution, 0.01% • GlobeNewswire Inc. • 04/09/2026 12:00:00 PM
- Amneal to Report First Quarter 2026 Results on May 1, 2026 • GlobeNewswire Inc. • 04/07/2026 08:01:00 PM
